VIVE - Viveve Medical, Inc.
| Previous Close | 3.11 |
| Open | 3.13 |
| Bid | 3.07 x 3000 |
| Ask | 3.10 x 800 |
| Day's Range | 3.07 - 3.20 |
| 52 Week Range | 1.60 - 6.00 |
| Volume | 15,702 |
| Avg. Volume | 459,882 |
| Market Cap | 97.299M |
| Beta | 0.79 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.83 |
| Earnings Date | May 9, 2018 - May 14, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.89 |
- GlobeNewswire•7 days ago
Viveve Initiates LIBERATE-International Trial for Improvement of Stress Urinary Incontinence
Viveve Medical, Inc. (VIVE), a medical technology company focused on women’s intimate health, announced today the initiation of LIBERATE-International, a multicenter, randomized, double-blinded, sham-controlled trial to evaluate the safety and efficacy of its proprietary, cryogen-cooled monopolar radiofrequency (CMRF) technology for the improvement of stress urinary incontinence (SUI) in women. “Initiation of LIBERATE-International represents a significant advance in our pursuit of regulatory clearances for the treatment of SUI, a condition that effects an estimated 25-30 million women worldwide.
- GlobeNewswire•12 days ago
Viveve Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Company reports 80% growth in total quarterly revenue year-over-year Multiple clinical and regulatory milestones achieved for Viveve ® System ENGLEWOOD, Colo., Aug. 09, 2018-- Viveve Medical Inc., a medical ...
- ACCESSWIRE•12 days ago
Viveve Medical Inc to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Viveve Medical Inc (NASDAQ: VIVE ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 5:00 PM Eastern Time. ...
- GlobeNewswire•14 days ago
Viveve Announces FDA Approval to Continue VIVEVE II Clinical Study
Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to continue enrollment in the company’s multicenter randomized Viveve Treatment of the Vaginal Introitus to EValuate Safety and Efficacy (VIVEVE II) clinical trial to assess the safety and effectiveness of the Viveve® System for the improvement of sexual function in women following vaginal childbirth. The Agency’s approval was based on a determination that the company provided sufficient data to support continued subject enrollment in the trial and that there are no subject protection concerns that preclude continuation of the study.
- Zacks Small Cap Research•19 days ago
VIVE: FDA Warning Letter Should Weed-Out Imposters and Benefit VIVE
On July 30th FDA issued a Safety Communications letter warning against the use of “Energy-Based Devices to Perform Vaginal ‘Rejuvenation’ of Vaginal Cosmetic Procedures”. The purpose of the letter is to “alert patients and health care providers that the use of energy-based devices to perform vaginal "rejuvenation," cosmetic vaginal procedures, or non-surgical vaginal procedures to treat symptoms related to menopause, urinary incontinence, or sexual function may be associated with serious adverse events. FDA notes that they are aware of certain device manufacturers that may be marketing for these purposes – none of which are approved for those indications.
- GlobeNewswire•19 days ago
Viveve to Announce Financial Results for Second Quarter 2018 and Host Conference Call
Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, will announce financial results for the second quarter ended June 30, 2018 on Thursday, August 9, 2018 after the close of the U.S. financial markets. The company will also host a live conference call and webcast to discuss these financial results and provide an update on corporate and commercial developments. The conference call may be accessed by dialing 1-833-255-2833 (domestic) or 1-412-902-6723 (international) or via live webcast at https://services.choruscall.com/links/vive180809.html.
- GlobeNewswire•last month
Viveve Reports Preliminary Second Quarter 2018 Revenue of $5.5 million
Viveve Medical Inc. (VIVE), a medical technology company focused on women's intimate health, today reported preliminary financial results for the second quarter ended June 30, 2018. Estimated total product revenue for the three months ended June 30, 2018, is expected to be approximately $5.5 million, representing a 79% increase over total product revenue for the quarter ended June 30, 2017. The company also announced today that it has entered into a capital sales partnership with Aesthetic Management Partners, Inc. (“AMP”) to expand its commercial footprint in the U.S.
- ACCESSWIRE•2 months ago
Free Technical Research on Abbott Laboratories and Three More Medical Equipment Equities
On Tuesday, July 03, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Taking into consideration last Tuesday's market sentiment, WallStEquities.com assessed the following Medical Appliances & Equipment equities this morning: Viveve Medical Inc. (NASDAQ: VIVE), Abbott Laboratories (NYSE: ABT), ABIOMED Inc. (NASDAQ: ABMD), and Align Technology Inc. (NASDAQ: ALGN). On Tuesday, shares in Englewood, Colorado headquartered Viveve Medical Inc. recorded a trading volume of 213,805 shares.
- GlobeNewswire•2 months ago
Viveve Submits VIVEVE II Clinical Study 30-Day Patient Safety Data to FDA
Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that it has submitted 30-day patient safety data to the U.S. Food and Drug Administration (FDA) for 38 subjects completing the 1-month assessment in the company’s multicenter randomized Viveve Treatment of the Vaginal Introitus to EValuate Safety and Efficacy (VIVEVE II) clinical study. “Submission of this safety data addresses the FDA’s request to review the 30-day safety data from at least 25 patients in the VIVEVE II study and represents a major step forward in the progression of the VIVEVE II trial,” said Scott Durbin, chief executive officer of Viveve.
- Zacks Small Cap Research•2 months ago
VIVE: Compelling SUI Feasibility Study 6-Month Data. SUI LIBERATE RCTs On-Deck
Last week Viveve (VIVE) announced what we would characterize as potentially compelling 6-month data from its ongoing SUI 12-month feasibility study. Listed under clinicaltrials.org Identifier: NCT03066180, the single-arm, 36-subject study is being conducted at Dr. Bruce Allan’s Allan Centre (Dr. Allan was also the principal investigator for the VIVEVE I vaginal laxity/sexual function study) in Calgary, Canada. While only a single-arm feasibility study, it was clearly designed to be consistent with FDA's recommendations for SUI-device pivotal studies (FDA's guidance for Clinical Investigations of Devices Indicated for the Treatment of Urinary Incontinence).
- Simply Wall St.•2 months ago
What Is Viveve Medical Inc’s (NASDAQ:VIVE) Share Price Doing?
Viveve Medical Inc (NASDAQ:VIVE), a medical equipment company based in United States, received a lot of attention from a substantial price increase on the NasdaqCM over the last few months.Read More...
- GlobeNewswire•2 months ago
Viveve Reports Positive Six-Month Data from Stress Urinary Incontinence Feasibility Study
Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today reported positive and sustained six-month data from an ongoing single-arm feasibility study using its cryogen-cooled, monopolar radiofrequency (CMRF) technology platform for the treatment of mild-to-moderate stress urinary incontinence (SUI) in women. The ongoing study is being conducted by Bruce Allan, PhD, MD, FRCS(C), founder and medical director of the Allan Centre in Calgary, Alberta. “These new data are extremely encouraging for women suffering from stress urinary incontinence, further validating the positive 12-month SUI pilot study data that we reported in February.
- GlobeNewswire•3 months ago
Viveve Announces Settlement of Patent Infringement Litigation with Thermi
Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced that is has reached a settlement to resolve the patent litigation that it filed in 2016 against ThermiGen, LLC, ThermiAesthetics, LLC, and Dr. Red Alinsod in the U.S. District Court for the Eastern District of Texas citing infringement of Viveve’s intellectual property (Viveve, Inc. v. ThermiGen, LLC, No.2:16-1189). Under the settlement, Viveve will receive a monetary payment and on-going royalty, as well as other mutual agreements relating to certain intellectual property owned by the companies.
- GlobeNewswire•3 months ago
Viveve to Present at Jefferies Global Healthcare Conference
Viveve Medical, Inc. is a women's intimate health company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve® System, that delivers the Viveve treatment, incorporates clinically-proven cryogen-cooled, monopolar radiofrequency (CMRF) technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate robust neocollagenesis in a single 30-minute in-office session.
- Zacks Small Cap Research•3 months ago
VIVE: Q1 Results: Disappointing But Not All Was Bad. Guidance Intact But That May Now Be More Challenging
Viveve (VIVE) reported Q1 2018 financial results and provided a business update. Despite what we’d characterize as a pretty disappointing start to the year, management reiterated their previously issued 2018 revenue guidance in the range of $22M (+44%) to $24M (+57%). VIVE indicated that realignment of the sales force/territories and a national sales meeting (which sidelined the entire sales force for a week) significantly impacted Q1 domestic sales results.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of VIVE earnings conference call or presentation 10-May-18 9:00pm GMT
Q1 2018 Viveve Medical Inc Earnings Call
- Zacks Small Cap Research•5 months ago
VIVE: Q4 Results: 108% Sales Growth in Q4. 2018 Catalysts Include Doubling+ Sales Force, SUI-Related Adoption, VIVEVE II
The business update encompassed several near-term goals including further significant growth of the direct sales force, regulatory approval and entry into additional territories, progress towards label expansion, introduction of complementary products and continued strong revenue and margin growth. Just days after the Q4 earnings announcement, VIVE received notice that FDA approved their IDE to conduct ‘VIVEVE II’, the clinical trial which is expected to serve as primary support for an eventual U.S. regulatory filing seeking clearance for a ‘sexual-function’ related indication. While very long-in-the-tooth, the IDE approval was welcome news as it means that Geneveve could relatively soon be the only energy-based technology cleared by FDA for such an indication.
- Marketwired•5 months ago
Viveve Announces FDA Approval of IDE to Conduct VIVEVE II Clinical Study
Viveve Medical, Inc. , a medical technology company focused on women's intimate health, today announced it received approval of its Investigational Device Exemption application from the U.S. Food and Drug ...
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of VIVE earnings conference call or presentation 15-Mar-18 9:00pm GMT
Q4 2017 Viveve Medical Inc Earnings Call
- American City Business Journals•5 months ago
Colorado women's sexual health company expanding; Q4, 2017 revenues rise
The company makes medical treatment for vaginal laxity, which occurs primarily after childbirth.
- Marketwired•5 months ago
Viveve Reports Fourth Quarter and Full Year 2017 Financial Results
Viveve Medical Inc. , a medical technology company focused on women's intimate health, today reported financial results for the three months and year ended December 31, 2017."Our successful fourth-quarter ...
